Research ExplorerPublicationsCancer-Specific Mortality Differences in Specimen-Confined R...

Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion

Standard

Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. / Barletta, Francesco; Tappero, Stefano; Morra, Simone; Incesu, Reha-Baris; Cano Garcia, Cristina; Piccinelli, Mattia Luca; Scheipner, Lukas; Baudo, Andrea; Tian, Zhe; Gandaglia, Giorgio; Stabile, Armando; Mazzone, Elio; Terrone, Carlo; Longo, Nicola; Tilki, Derya; Chun, Felix K H; de Cobelli, Ottavio; Ahyai, Sascha; Carmignani, Luca; Saad, Fred; Shariat, Shahrokh F; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

In: CLIN GENITOURIN CANC, Vol. 21, No. 6, 12.2023, p. e461-e466.e1.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Barletta, F, Tappero, S, Morra, S, Incesu, R-B, Cano Garcia, C, Piccinelli, ML, Scheipner, L, Baudo, A, Tian, Z, Gandaglia, G, Stabile, A, Mazzone, E, Terrone, C, Longo, N, Tilki, D, Chun, FKH, de Cobelli, O, Ahyai, S, Carmignani, L, Saad, F, Shariat, SF, Montorsi, F, Briganti, A & Karakiewicz, PI 2023, 'Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion', CLIN GENITOURIN CANC, vol. 21, no. 6, pp. e461-e466.e1. https://doi.org/10.1016/j.clgc.2023.05.010

APA

Barletta, F., Tappero, S., Morra, S., Incesu, R-B., Cano Garcia, C., Piccinelli, M. L., Scheipner, L., Baudo, A., Tian, Z., Gandaglia, G., Stabile, A., Mazzone, E., Terrone, C., Longo, N., Tilki, D., Chun, F. K. H., de Cobelli, O., Ahyai, S., Carmignani, L., ... Karakiewicz, P. I. (2023). Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. CLIN GENITOURIN CANC, 21(6), e461-e466.e1. https://doi.org/10.1016/j.clgc.2023.05.010

Vancouver

Barletta F, Tappero S, Morra S, Incesu R-B, Cano Garcia C, Piccinelli ML et al. Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. CLIN GENITOURIN CANC. 2023 Dec;21(6):e461-e466.e1. https://doi.org/10.1016/j.clgc.2023.05.010

Bibtex

@article{b0c768a94e3d4efdb0ae4b46a2a2af21,
title = "Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion",
abstract = "PURPOSE: To test cancer-specific mortality (CSM) differences in specimen-confined (pT2) prostate cancer (PCa) at radical prostatectomy (RP) with lymph node dissection (LND) according to lymph node invasion (LNI).METHODS: RP + LND pT2 PCa patients were identified (surveillance, epidemiology, and end results 2010-2015). CSM-FS rates were tested in Kaplan-Meier plots and multivariable Cox-regression (MCR) models. Sensitivity analyses respectively addressing patients with 6 or more lymph nodes analyzed and pT2 pN1 patients were performed.RESULTS: Overall, 32,258 patients with pT2 PCa at RP + LND were identified. Of these, 448 (1.4%) patients harbored LNI. Five-year CSM-free estimates were 99.6% for pN0 vs. 96.4% for pN1 (P < .001). In MCR models, pN1 (HR: 3.4, P < .001) independently predicted higher CSM. In sensitivity analyses addressing patients with 6 or more lymph nodes analyzed (n = 15,437), 328 (2.1%) pN1 patients were identified. In this subgroup, 5-year CSM-free estimates were 99.6% for pN0 vs. 96.3% for pN1 (P < .001) and, in MCR models, pN1 independently predicted higher CSM (HR: 4.4, P < .001). In sensitivity analyses addressing pT2 pN1 patients, 5-year CSM-free estimates were 99.3, 100 and 84.8% for ISUP GG 1-3 vs. 4 vs. 5, respectively (P < .001).CONCLUSIONS: In patients with pT2 PCa a small proportion harbor LNI (1.4%-2.1%). In such patients, CSM rate is higher (HR 3.4-4.4, P < .001). This higher CSM risk seems to virtually exclusively apply to ISUP GG5 patients (84.8% 5-year CSM-free rate).",
keywords = "Male, Humans, Lymphatic Metastasis/pathology, Lymph Nodes/surgery, Lymph Node Excision/methods, Prostate/pathology, Prostatic Neoplasms/pathology, Prostatectomy/methods",
author = "Francesco Barletta and Stefano Tappero and Simone Morra and Reha-Baris Incesu and {Cano Garcia}, Cristina and Piccinelli, {Mattia Luca} and Lukas Scheipner and Andrea Baudo and Zhe Tian and Giorgio Gandaglia and Armando Stabile and Elio Mazzone and Carlo Terrone and Nicola Longo and Derya Tilki and Chun, {Felix K H} and {de Cobelli}, Ottavio and Sascha Ahyai and Luca Carmignani and Fred Saad and Shariat, {Shahrokh F} and Francesco Montorsi and Alberto Briganti and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2023 Elsevier Inc. All rights reserved.",
year = "2023",
month = dec,
doi = "10.1016/j.clgc.2023.05.010",
language = "English",
volume = "21",
pages = "e461--e466.e1",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion

AU - Barletta, Francesco

AU - Tappero, Stefano

AU - Morra, Simone

AU - Incesu, Reha-Baris

AU - Cano Garcia, Cristina

AU - Piccinelli, Mattia Luca

AU - Scheipner, Lukas

AU - Baudo, Andrea

AU - Tian, Zhe

AU - Gandaglia, Giorgio

AU - Stabile, Armando

AU - Mazzone, Elio

AU - Terrone, Carlo

AU - Longo, Nicola

AU - Tilki, Derya

AU - Chun, Felix K H

AU - de Cobelli, Ottavio

AU - Ahyai, Sascha

AU - Carmignani, Luca

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Montorsi, Francesco

AU - Briganti, Alberto

AU - Karakiewicz, Pierre I

N1 - Copyright © 2023 Elsevier Inc. All rights reserved.

PY - 2023/12

Y1 - 2023/12

N2 - PURPOSE: To test cancer-specific mortality (CSM) differences in specimen-confined (pT2) prostate cancer (PCa) at radical prostatectomy (RP) with lymph node dissection (LND) according to lymph node invasion (LNI).METHODS: RP + LND pT2 PCa patients were identified (surveillance, epidemiology, and end results 2010-2015). CSM-FS rates were tested in Kaplan-Meier plots and multivariable Cox-regression (MCR) models. Sensitivity analyses respectively addressing patients with 6 or more lymph nodes analyzed and pT2 pN1 patients were performed.RESULTS: Overall, 32,258 patients with pT2 PCa at RP + LND were identified. Of these, 448 (1.4%) patients harbored LNI. Five-year CSM-free estimates were 99.6% for pN0 vs. 96.4% for pN1 (P < .001). In MCR models, pN1 (HR: 3.4, P < .001) independently predicted higher CSM. In sensitivity analyses addressing patients with 6 or more lymph nodes analyzed (n = 15,437), 328 (2.1%) pN1 patients were identified. In this subgroup, 5-year CSM-free estimates were 99.6% for pN0 vs. 96.3% for pN1 (P < .001) and, in MCR models, pN1 independently predicted higher CSM (HR: 4.4, P < .001). In sensitivity analyses addressing pT2 pN1 patients, 5-year CSM-free estimates were 99.3, 100 and 84.8% for ISUP GG 1-3 vs. 4 vs. 5, respectively (P < .001).CONCLUSIONS: In patients with pT2 PCa a small proportion harbor LNI (1.4%-2.1%). In such patients, CSM rate is higher (HR 3.4-4.4, P < .001). This higher CSM risk seems to virtually exclusively apply to ISUP GG5 patients (84.8% 5-year CSM-free rate).

AB - PURPOSE: To test cancer-specific mortality (CSM) differences in specimen-confined (pT2) prostate cancer (PCa) at radical prostatectomy (RP) with lymph node dissection (LND) according to lymph node invasion (LNI).METHODS: RP + LND pT2 PCa patients were identified (surveillance, epidemiology, and end results 2010-2015). CSM-FS rates were tested in Kaplan-Meier plots and multivariable Cox-regression (MCR) models. Sensitivity analyses respectively addressing patients with 6 or more lymph nodes analyzed and pT2 pN1 patients were performed.RESULTS: Overall, 32,258 patients with pT2 PCa at RP + LND were identified. Of these, 448 (1.4%) patients harbored LNI. Five-year CSM-free estimates were 99.6% for pN0 vs. 96.4% for pN1 (P < .001). In MCR models, pN1 (HR: 3.4, P < .001) independently predicted higher CSM. In sensitivity analyses addressing patients with 6 or more lymph nodes analyzed (n = 15,437), 328 (2.1%) pN1 patients were identified. In this subgroup, 5-year CSM-free estimates were 99.6% for pN0 vs. 96.3% for pN1 (P < .001) and, in MCR models, pN1 independently predicted higher CSM (HR: 4.4, P < .001). In sensitivity analyses addressing pT2 pN1 patients, 5-year CSM-free estimates were 99.3, 100 and 84.8% for ISUP GG 1-3 vs. 4 vs. 5, respectively (P < .001).CONCLUSIONS: In patients with pT2 PCa a small proportion harbor LNI (1.4%-2.1%). In such patients, CSM rate is higher (HR 3.4-4.4, P < .001). This higher CSM risk seems to virtually exclusively apply to ISUP GG5 patients (84.8% 5-year CSM-free rate).

KW - Male

KW - Humans

KW - Lymphatic Metastasis/pathology

KW - Lymph Nodes/surgery

KW - Lymph Node Excision/methods

KW - Prostate/pathology

KW - Prostatic Neoplasms/pathology

KW - Prostatectomy/methods

U2 - 10.1016/j.clgc.2023.05.010

DO - 10.1016/j.clgc.2023.05.010

M3 - SCORING: Journal article

C2 - 37365054

VL - 21

SP - e461-e466.e1

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 6

ER -